Table 3.

Baseline characteristics by QTc prolongation or TdP requiring dose change.

	Total Cohort			Same dose reloading
	QTc prolongation or TdP		P Value	QTc prolongation or TdP		P Value
	No N=94 (68.1%)	Yes N=44 (31.9%)		No N=72 (70.6%)	Yes N=30 (29.4%)
Age, years	64.8 ± 11.9	64.2 ± 11.3	0.77	62.4 ± 11.5	62.5 ± 11.4	0.96
Male sex	70 (74.5)	30 (68.2)	0.44	54 (75.0)	21 (70.0)	0.60
Hypertension	76 (80.9)	41 (93.2)	0.076	57 (79.2)	28 (93.3)	0.14
Diabetes mellitus	16 (17.0)	14 (31.8)	0.05	15 (20.8)	9 (30.0)	0.32
Hyperlipidemia	52 (55.3)	25 (56.8)	0.87	42 (58.3)	19 (63.3)	0.64
Chronic kidney disease	13 (13.8)	7 (15.9)	0.75	12 (16.7)	3 (10.0)	0.54
Coronary artery disease	24 (25.5)	13 (29.5)	0.62	19 (26.4)	6 (20.0)	0.49
Congestive heart failure	48 (51.1)	18 (40.9)	0.27	39 (54.2)	12 (40.0)	0.19
Left ventricular ejection fraction, %	48.4 ± 12.2	50.1 ± 12.2	0.48	47.8 ± 12.5	49.7 ± 12.6	0.51
Creatinine clearance, ml/min	108.2 ± 42.5	105.8 ± 36.0	0.75	112.8 ± 40.3	107.5 ± 38.1	0.54
Pacemaker	17 (18.1)	4 (9.1)	0.21	12 (16.7)	3 (10.0)	0.54
Implantable cardioverter defibrillator	13 (13.8)	4 (9.1)	0.58	9 (12.5)	4 (13.3)	1.00
Dose higher than recommended by CrCl	4 (4.3%)	0 (0%)	0.31	1 (1.4%)	0 (0%)	1.00
Dofetilide dose increase	19 (20.4)	11 (26.8)	0.41	Not applicable	Not applicable	Not applicable
ECG Intervals before Reload, ms
QRS duration	108.1 ± 25.9	100.6 ± 23.8	0.11	107.1 ± 22.8	96.9 ± 21.3	0.039
QT	396.6 ± 51.6	402.4 ± 53.0	0.54	394.9 ± 43.6	398.0 ± 48.9	0.75
QTc	449.6 ± 37.4	460.1 ± 32.8	0.11	446.5 ± 36.1	461.0 ± 30.8	0.058
Adjusted QTc	436.6 ± 31.8	451.8 ± 30.7	0.009	435.1 ± 30.9	455.6 ± 31.6	0.003
Calculated JTc	341.5 ± 32.4	359.5 ± 30.3	0.002	339.4 ± 31.1	364.0 ± 30.4	<0.001